PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

Findings seen in adults aged 40 to 80 years with at least two cardiovascular risk factors. (HealthDay News) — For adults with an increased cardiovascular risk, elevated C-reactive protein (CRP) levels ...

The FDA has approved Degevma (denosumab-adet), a new biosimilar to Xgeva, to prevent skeletal-related events in patients with bone metastases.

The effects of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online Sept. 23 in the European Heart Journal.

Trial investigators evaluated the prognostic and predictive ability of PAM50 molecular prostate cancer subtypes to guide salvage treatment.

Dr Rena Malik is a board-certified urologist, pelvic surgeon, and sexual health expert whose social media channels educate millions of subscribers. Dr Rena Malik is a board-certified urologist, pelvic ...

Men with frailty have higher risk for cognitive impairment than men without frailty, but no association seen in women.

The pre-formed and radiopaque flex hydrogel spacer is now FDA approved and will begin limited distribution in the US. The US Food and Drug Administration (FDA) has granted 510 (k) clearance for ...

Chronic pain was most common patient-reported qualifying condition, accounting for 64.5 and 31.9 percent in 2016 and 2024.

A randomized trial tested lactoferrin added to oral iron therapy in patients with advanced chronic kidney disease (CKD) and iron-deficiency anemia.